StockNews.AI
ZYXI
StockNews.AI
5 days

Zynex, Inc. Investors: Company Investigated by the Portnoy Law Firm

1. Portnoy Law Firm investigates potential securities fraud at Zynex. 2. Allegations include false statements about financial performance and operations. 3. Zynex's revenue from Tricare, 20-25%, is under scrutiny due to payment suspensions. 4. Share price plummeted 51.3% following revenue shortfall revelations. 5. Class action may be filed against Zynex for misrepresentation of facts.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The allegations of fraud and revenue shortfalls suggest severe risks similar to prior instances like Enron.

How important is it?

Legal issues reveal deep vulnerabilities impacting investor confidence and stock price.

Why Short Term?

Immediate legal actions could lead to volatile price movements in the next weeks.

Related Companies

TRICSMEDOMAB
Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Zynex, Inc. (“Zynex” or “the Company”) (NASDAQ:ZYXI) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Zynex investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. The complaint alleges that the Individual Defendants artificially inflated Zynex’s stock price by issuing, or causing to be issued, false and misleading statements regarding the Company’s financial performance, operational practices, and compliance with insurance reimbursement policies. In particular, Defendants concealed a systemic “oversupplying scheme” under which Zynex shipped excessive quantities of supplies, including electrode pads and batteries, to patients and billed insurers for amounts far exceeding what was necessary. These undisclosed practices drew scrutiny from insurers, including Tricare—the federal health insurer for the military—which accounted for approximately 20% to 25% of Zynex’s annual revenue. The truth began to emerge on March 11, 2025, when Zynex issued a press release announcing its fourth-quarter and full-year 2024 results, disclosing a significant revenue shortfall attributed to “slower than normal payments from certain payers” and revealing that “Tricare has temporarily suspended payments as they review prior claims.” The disclosure that Tricare—representing a substantial portion of the Company’s revenue—was scrutinizing prior claims threatened Zynex’s financial stability. On March 12, 2025, Zynex’s stock price fell $3.59 per share, or 51.3%, to close at $3.41 per share, erasing significant shareholder value and reflecting the market’s reaction to the Company’s previously undisclosed regulatory and financial risks. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq.Admitted CA, NY and TX Barslesley@portnoylaw.com310-692-8883www.portnoylaw.com Attorney Advertising

Related News